In addition, for precancerous lesions of breast cancer, the main therapeutic drugs are estrogen receptor modulators or aromatase inhibitors, which eventually lead to endocrine disorders and increase the possibility of developing endometrial cancer or uterine fibroids and sarcomas [33]. Here, CYP19A1 is linked to endometrial cancer.